

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**

**宜昌東陽光長江藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 01558)**

## **SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO ANNUAL REPORT 2023**

Reference is made to the annual report of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year 2023 (the “**Annual Report**”) and the announcement of the Company dated 26 April 2024 regarding the continuing connected transactions in relation to the Sharing Agreement (the “**Announcement**”). Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Annual Report and the Announcement.

In addition to the information provided in the Annual Report, the Board would like to provide the following supplementary information to the Annual Report, and the Annual Report shall be read in conjunction with the information below.

Paragraph D.2.4 of Appendix C1 of the Listing Rules provides that the Board has the overall responsibility to maintain sound and effective risk management and internal control systems for the Group to ensure that major risks that may impact the Company’s performance are appropriately identified and managed to provide reasonable, though not absolute, assurance against material misstatement or loss, and to manage rather than eliminate the risk of failure to achieve business objectives. During the Reporting Period, a series of risk management and internal control measures were put into place by the Board, details of which were disclosed in the Annual Report.

Despite the fact that the Original Proposed Annual Caps were exceeded, details of which were set out in the Announcement, in general and as a whole, the Board (including the audit committee of the Company) is of the view that the Company’s risk management and internal control measures during the Reporting Period have been effective in assisting the Board in identifying risks through its internal control system under which measures, plans and mechanisms were implemented to reasonably manage these risks and prevent material loss or non-compliance. In reaching such a conclusion, the Board (including the audit committee of the Company) had considered the main objectives of its risk management and internal

control systems, namely, inter alia, to safeguard assets, ensure proper maintenance of accounting records, and provide reliable financial reporting, as well as to ensure compliance with relevant legislation and regulations.

With the implementation of the remedial measures and internal control measures as detailed in the Announcement, the Board (including the audit committee of the Company) is of the view that such measures will be able to ensure continued compliance with Chapter 14A of the Listing Rules and prevent the occurrence of similar incidents in the future.

The above supplementary information does not affect other information contained in the Annual Report. Save as disclosed above, all other information in the Annual Report remains unchanged.

On behalf of the Board  
**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**  
**TANG Xinfu**  
*Chairman*

Hubei, the PRC  
7 June 2024

*As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. LI Shuang and Mr. CHEN Hao as executive Directors; Mr. TANG Xinfu as non-executive Director; and Mr. TANG Jianxin, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive Directors.*